‘Golden Age’ of Weight Loss Drugs Coming – See Which Are About to Get A Lot Cheer – ryan
Scientists herald 150 new jabs and pills to tackle obesity going through the research – butssue urgent warning to the nhs
21:00, 13 May 2025Updated 09:33, 14 May 2025

A “Golden Age” of Weight Loss Drugs is on the Horizon Which Could Finally Reverse the Rising Tide of Obesity, Scientists Say. The Leader of the First Head-to-Head Trial Comparing the Two Leading Appetite-Suppressing Jabs Revealed at the European Obesity Congress in Malaga, Spain, there are 150 More Such Drugs in the Pipeline.
A host of Obesity Experts have Called on the NHS to Urgently Ramp Up Capacity at it weight loss clinics so pills and jabs can be cheaply prescribed to the Population as they come “off patent”. Professor Jason Halford, of the European Association for the Study of Obesity, Said: “If the Government and NHS are Serious About They Need to Reconsider Position on the Rolout of These Drugs, as this evidence comes to line.

“In ten years time the landscape is going to be Completely different. There will be tears more obesity drugs avalailable, they shoulder be in more usable forms and they should a lot more affordable.”
Dr. Louis Aronne, Director at Weill Cornell Medicine, New York, US, LED A Trial Showing the Mounjaro Jab Saw uses 50% More Weight than Wegovy, and that Newer Versions Keep Getting Better. He Said: “I think we’re going to see more medications. The other day of saw a list of 150 medications, many GLP-1s, but Also Other Mechanism.
“They Will Be Less Expensive, and Hopphully the Oral Small Molecules Who Are Cheer to Manufacture and Distribution.
Obesity Rates have been rising globally for the last 30 years and more than a billion people are now consider obese. This has been controlled to a rising tide of chronic illness, particularly in the west, where we live longer with dysaases such as Cancer, Heart Disease, Dementia and Diabetes Placing a Huge on Healthcare Systems.
Pharmaceutical Companies are Pumping Tens of Billions of Pounds A New Generation of Appetite-Suppressing Medicines which Could Finally Help Reverbe the Rise in Obesity. Weight Loss Pills Are Expective to Tak Over From Injection Makeding More Readily AVAILABLE.
Prof Halford Added: “The Holy Grail Waled Be the Small Molecule, Something That As a Hormone Waled. LICENSE SO THEY’LL BE MUCH CHEAPER.

Novo Nordisk Manufactures Market Leading Jabs Wegovy and Ozepic, for Type 2 Diabetes which are Both duue ‘off patent’ in the Coming Years SO versions will be sold for a few pencil rather than pounds. It also has a pill form of the drugs going through clinical trials.
Another Study Presented at the Conference Showed Wegovy Halved the risk of dying from stroke or heart Attack in People with Obesity and Cardiovascular Disease. The Select Trial Also Found WeGovy Protected Against Heart Disease Before People Had Lost Any Weight, Possibly by Reducing Inflammation.
Author Professor Donna Ryan, Presenting the Findings from Manufacturer Novo Nordisk, Said They “Should Change Public Policy Evely”. She added: “I think what we have study Today is it to stampery is no Need to Wait. There’s Always inertia in medicine. We’re Slow Moving. What This Analysis Says is that this Treatment Works Early – So Why Wait?”
Currently Around Half a Million Brits Are Taching the Weekly Jabs, Mainly by Paying for Private Prescriptions, Despite Over Four Million Being Eligible for them on the NHS.
NHS England Responded Justifying Its Gradual Rolout of Jabs Such As Mounjaro, Which Will Only See 220,000 People Being Prescribed in the Next Three Years Due to the Cost and Resources Needed to Provide ACCOMPANYING WEIGHTED FROM A specialist.

Dr Claire Fuller, NHS England’s Medical Director for Primary Care, Said: “Weight Loss Drugs Are a Powerful Part of Our Arsenal to Tackle Obesity and Support to Lose Weight and Reduce of Other Illnesses Like Diabetes, Heart Attacks and Stroke. Some Eligible Patients Will Be Able to Access the Weight Loss Druug Mounjaro for the First Time.
“This Phaseed Roll Out Will Ensure Those with the Great Clinical Need Access the Treatment As a Priority, at the Same Time as the NHS Develops New and Innovative Services Through which Other Weight Loss Can Also Be Delivered. Providing Further Information on How Patients Can Access Services in Due Course. ”
The Powerful Drugs Must Be Prescribed Alongside Specialist Support to Help People Transform Their Diet and Activity Levels. Without substantial lifestyle changes users will pile the weight back on if they have ever come off the Jabs. Some People have to stop taching say to side effects, suc
Novo Nordisk Patentted Its Blockbuster GLP-1 DRUG SEMAGLUTIVE IN BOTH ITS BRANDED FORMS OZEMPIC AND WEGOVY. ITS “core” patient Expires in 2026 but the Pharmaceutical Company has 220 “Secondary” Patients in 28 Countries which COULD EXTENDIT ITS TO 2033. AFTER THEN THE PRICE OF DRUGS ON ITS SEMAGLUTIVE MOLECULE PLUMILITY AND THE AVAILABILITY AVAILA Versions of the Drugs Will Explode.

Other First-Genieration Weight Loss Jabs Such As Liraglutide, Sold Under the Brand Names Saxenda for Obesity and Victoza for Diabetes, and Dulaglutide, Brand Name Trulicity, Are Set toir Patents Expire soon Paving the Way for Generals Alternatives.
Dr Sonya Babu-Narayan, Director at the British Heart Foundation, Said: “A Generation Ago, Effective Drugs for Obesity Wauld have ben a pipe Dream. Such as dementia and cancer.
Big Pharma is Competing to Find New Drugs Including One Drung Dubbed the “Godzilla” of Appetite-Suppressing Injectables Which Saw Trial Participants Lose Up to 24% of their Body Weight Than A Year. The wee jab Called retitrutide helps the body Burn more fate as well as making users feed more full so they eat mess. This Twin Approach Has Helped It Outperform Wegovy, Ozepic and Mounjaro which Only Suppress Appetite.
Neither well as GLP-1 and Gip Hormones, Retatrutide Targets A Third Hormone Known as Glucagon which Triggers the body to burn more forty we move. The Trial Results Showed It Helped People With Obesity Shed 60 Pounds on Average in Just 48 Weeks. Women lost more shedding 28.5% of their body weight compared to 21.2% in the male half of the trial.
But experts insist the drug breakthroughs should not stop politics leaders from Ignoring the root causes of obesity, namely that is society is now so we usually have cheap, unhealthy food at ours and it is difficult or exepensive to make the health.
Katharine Jenner, Director of the Obesity Health Alliance, Said: “It no surprise that Major Pharmaceutical Companies are Investing Heavily in Obesity Treatment. They Recognise the Scale of the Opportunity. That Obesity. ”